Weekly Research Analysts’ Ratings Updates for 4D Molecular Therapeutics (FDMT)

Several brokerages have updated their recommendations and price targets on shares of 4D Molecular Therapeutics (NASDAQ: FDMT) in the last few weeks:

• 10/22/2026 – 4D Molecular Therapeutics had its “buy” rating reaffirmed by Citigroup.
• 10/22/2026 – 4D Molecular Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $36.00 price target on the stock.
• 10/15/2026 – 4D Molecular Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/6/2026 – 4D Molecular Therapeutics had its price target lowered by Chardan Capital from $26.00 to $25.00. They now have a “buy” rating on the stock.
• 9/29/2026 – 4D Molecular Therapeutics had its price target raised by Bank of America from $29.00 to $33.00. They now have a “buy” rating on the stock.
• 9/14/2026 – 4D Molecular Therapeutics was upgraded by Cantor Fitzgerald from “neutral” to “overweight”. They now have a $20.00 price target on the stock.

Insider Activity at 4D Molecular Therapeutics

In related news, insider David Kirn sold 58,333 shares of the firm’s stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $12.92, for a total transaction of $753,662.36. Following the transaction, the insider owned 709,153 shares in the company, valued at $9,162,256.76. This trade represents a 7.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 136,205 shares of company stock worth $1,780,316 in the last quarter. 7.90% of the stock is owned by company insiders.

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases with significant unmet medical needs. The company uses its Therapeutic Vector Evolution platform to design adeno-associated virus (AAV) vectors intended to deliver genetic medicines to specific tissues and organs.

Its pipeline has focused primarily on ophthalmology and pulmonology. Key investigational programs have included 4D-150, an intravitreal gene therapy being developed for retinal diseases such as wet age-related macular degeneration and diabetic macular edema, and 4D-710, an inhaled gene therapy designed to address the underlying cause of cystic fibrosis in patients who cannot benefit from existing CFTR modulator treatments.